Could AbbVie Inc. (ABBV) Win as Genmab A/S (GMAB) Faces a New Regulatory Test for Epcoritamab?

insidermonkey.com · 2026-08-13

On July 23, Genmab A/S (NASDAQ:GMAB) and AbbVie Inc. (NYSE:ABBV) clarified a key clinical setback regarding their jointly developed T-cell engaging bispecific antibody, epcoritamab (DuoBody-CD3xCD20).

TickrTrends take: Genmab faces regulatory scrutiny on epcoritamab, a key asset in its pipeline that could meaningfully impact the company's value creation trajectory. Given TickrTrends' current undervalued assessment of GMAB in the healthcare sector, investors monitoring the stock should track the regulatory outcome closely, as approval or setback would represent a material catalyst affecting the company's commercial prospects and justification for its current valuation. The competitive dynamic with AbbVie adds an additional layer of risk that valuation-focused observers should weigh against GMAB's current pricing.

Read the full story at insidermonkey.com →